Project description
AI and robotics redesign drug discovery
Pharmaceutical research and development often ends in failure. Creating a new medicine usually takes over a decade and costs billions of euro. This problem highlights the urgent need to rethink how new drugs are discovered and delivered to patients. The EIC-funded AIR-3D project presents a closed-loop platform that combines generative AI with automated synthesis and testing. By merging software with robotics, the platform designs new molecules on a computer, quickly synthesises them in the lab, and learns from actual results. This method could reduce discovery timelines from five years to just two, significantly improving efficiency and success rates. AIR-3D seeks to transform pharmaceutical research and development and accelerate access to life-saving treatments.
Objective
Drug discovery is a lengthy and costly process, often exceeding a decade and involving investments upwards of €1.3bn. Despite these efforts, a staggering 90% of drug candidates fail in clinical trials, never reaching patients. This inefficiency underscores the urgent need for innovation in drug discovery methodologies.
Iktos proposes a transformative approach with its closed-loop AI-guided autonomous drug discovery platform, leveraging generative AI and built-in synthetic accessibility. This paradigm shift addresses key challenges in traditional drug discovery, including the generation of truly novel molecules, the speed of synthesis, and the management of high-dimensional data. Central to Iktos' solution are advanced SaaS platforms such as Makya and Spaya, powered by AI for rapid exploration of vast chemical spaces and efficient synthesis route planning. In this EIC Accelerator project, we want to combine AI and robotics to form a closed-loop, data-informed discovery platform, integrating AI-driven automated synthesis and testing into our workflow. Combined together these technologies enable the in silico design of optimal molecules and their corresponding synthesis in the lab to generate real-life data, accelerating the drug discovery timeline from an average of 5 years to just 2 years. Iktos' innovative approach leverages AI and robotics' potential to revolutionize pharmaceutical R&D, offering promising solutions to enhance the efficiency and success rate of bringing new medicines to patients globally.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- engineering and technology electrical engineering, electronic engineering, information engineering electronic engineering robotics
You need to log in or register to use this function
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
HORIZON.3.1 - The European Innovation Council (EIC)
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
HORIZON-EIC-ACC - HORIZON EIC Accelerator
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) HORIZON-EIC-2024-ACCELERATOR-02
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
75017 Paris
France
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.